NRSN · NeuroSense Therapeutics Ltd
United States · RS rating 75 · As of 2026-11-03
| Price | 1.28 USD |
|---|---|
| 1-day change | -10.5% |
| RS rating (overall / 1M / 3M / 12M) | 75 / 2 / 97 / 63 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 25 / 51 / 25 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +82.7% |
| Market cap (USD) | $25.3M |